Halozyme Therapeutics | HALO - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.83B 130M 2026-03
Baxter International USD 66M 280.2M 2026-03
Cara Therapeutics USD -5.94M 3.55M 2025-09
Cytokinetics USD -181.23M 2.86M 2026-03
DBV Technologies USD -34.28M 6.83M 2025-09
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -118M 97M 2026-03
MannKind USD -76.99M 7.75M 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Pfizer USD 4.99B 340M 2026-03
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
United Therapeutics USD 325.8M 340.4M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12